Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Mar 16, 2023
3 Tips to Be Successful in Trading

3 Tips to Be Successful in Trading

Stock trading may not be suitable for everyone as it requires a specific personality type to handle the pressure and maintain the discipline needed for success. Newbies often experience a high burnout rate, but those who persevere can achieve an unparalleled profit ceiling.

If you're considering a career in stock trading or already on your journey and looking to improve, pay close attention to the three tips in this article. We've kept it simple and avoided overwhelming you with a long "Best Practices" list.

Why only three tips? As a trader, you'll appreciate that the number three is the minimum required to establish a pattern. When analyzing a chart pattern, two points don't provide enough information. It's the third point that confirms the pattern.

Our goal was to avoid overwhelming you with a lengthy list of "how to" suggestions that could hinder your progress. Your job is straightforward: buy low and sell high. Anything else is just noise. Follow these tips, and you'll succeed.

Tip #1:  Self-Reflection

In 2017, Forbes Magazine published an article stating that 90% of day traders fail to turn a profit. This statistic highlights the number of inexperienced traders in the market. Unlike gambling, where the odds are stacked against you, successful stock trading requires proper execution and strategy.

Self-reflection is a crucial skill for traders to develop. It involves identifying and correcting mistakes, bad habits, and patterns that result in losses. Repeating the same unsuccessful actions and expecting different outcomes is the definition of insanity. Therefore, if a plan isn't working, it needs to be modified or replaced.

However, having a plan is only the first step. Novice traders often react to market changes instead of anticipating them. This reactive approach is counterproductive and can lead to impulsive decision-making. All-in trades to compensate for recent losses are a cautionary tale in the trading world.

A self-reflective trader takes time to evaluate their trading plan continually. However, assessing risk in the middle of the trading day indicates fear and not intelligence. Before the trading day begins, it's best to determine the amount to invest in each trade and execute the plan accordingly. Evaluation should occur after executing the plan.

Mistakes are often more apparent in hindsight. However, we are not referring to losses, as they can occur for various reasons. Sometimes, uptrends and downtrends do not happen as predicted by chart patterns, and that is not within your control. However, ignoring the patterns is your responsibility.

Another potential issue to keep in mind is your behavior. To be a successful day trader, it is necessary to be present and committed. Taking excessive breaks or deviating from your plan are behavioral errors. You can identify these mistakes by practicing self-reflection.

It could be that you are better at shorting the market than going long based on your risk to return ratio. Once you recognize this about yourself through self-reflection, it's crucial to stick to what you know and not try to be something you are not.

Finally, it's essential to reflect on unique patterns that lead to losses. Like baseball players who struggle with certain pitches, traders can have trouble with specific patterns. If you consistently face losses due to a pattern, avoid trading based on that pattern.

In 12-step recovery programs, this exercise is known as a "personal inventory." Create a list of all the aspects of trading you should pay attention to and use it daily to reflect on your trading activities. It's a crucial exercise that will help you become a better trader.

Check our Stock Market Live Today  

Tip #2: Full Concentration 

  • A successful trader must possess the patience and single-minded focus of a hunter lying in wait for their prey at the watering hole. To avoid the potential losses that can result from unexpected interruptions and external stimuli, it's crucial to create a workspace with zero disturbances. Here are some tips to help you set up an optimal trading environment:
  • First, set up a dedicated workspace that is separate from common areas and has good ambient lighting. This can be an in-home office or any other space where you won't be disturbed.
  • Second, upgrade your internet service to ensure a stable, high-speed connection. Invest in a new computer with an Intel Core Processor that's seventh generation or better to ensure optimal speed.
  • Third, invest in a quality pair of noise-cancelling headphones to eliminate background noise. Listening to non-lyrical music, such as classical or soft rock instrumental, can also help you stay focused.
  • Fourth, have a discussion with family members or roommates to let them know about your trading activities and establish boundaries. Consider using a "do not disturb" sign for your workspace.
  • Fifth, power off your mobile phone during trading hours and schedule breaks to check for missed calls and messages.
  • Sixth, remove the television from your workspace as it can be a distraction. Instead, use technical analysis and chart patterns from platforms like Tickeron to make trade decisions.
  • Finally, stick to a strict schedule that includes starting and ending your day at the market's opening and closing bell, scheduling breaks for specific times, and closing out all trades or setting stop losses before stepping away from the computer. By following these suggestions, you can create an optimal trading environment and focus exclusively on your trading activities.

This will help you concentrate exclusively on your trading activities. Check our Market Overview

Tip #3: Strict Risk Management  

If you're new to the world of trading, it's important to understand that the definition of risk is vastly different from what you may be accustomed to in other contexts. While in the non-trading world, risk is often viewed as a long-term concept, such as with 401(k) or Roth IRA investments, in the trading world, risk is evaluated on a trade-by-trade basis and is a more scientific concept.

The most successful traders know exactly how much they are willing to risk per trade and develop a plan for making a certain number of trades per day. This process is known as risk management, and it is critical to long-term success in trading.

Developing effective risk management strategies takes time and practice, so we strongly recommend exploring and refining your techniques using a trading simulator before using real money. One of the best tools available for this purpose is Tickeron's Paper Trade application. Take the time to master risk management before putting your hard-earned money at risk.

It's important to maintain a consistent risk management strategy even if you incur heavy losses in the early part of a trading session. It's not uncommon for traders to experience losses initially and then recover as the day progresses. To increase your chances of success, cultivate good study habits and maintain consistency between sessions.

Keep your emotions in check when trading, whether you're on the trading floor or online. If you want to trade based on "gut feelings," consider setting up a Robinhood account, where many inexperienced traders tend to congregate.

This recommendation aligns with the previous two we've presented: 1) engage in self-reflection, and 2) fully concentrate when trading. Additionally, adhere to a strict risk management strategy. By following these guidelines, you'll be better positioned to succeed in your profession.

Tickeron's Products

The main idea behind technical analysis is the ability to find recurring price patterns and trends and use them to predict the direction of future market trends. We started with the creation of AI-based Engines (Pattern Search Engine, Real-Time Patterns, Trend Prediction Engine) that allow us to effectively analyze market trends.  We then have explored almost all existing methods (price patterns, trend indicators, oscillators, and many others) using neural networks and deep historical backtests. As a result, it was possible to form a pool of trading algorithms that together allow our AI Robots to effectively determine the key points of change in market trends.

 


Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Interact to see
Advertisement
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.
Shares of GSAT are surging approximately +15% intraday on March 25, 2026, following a prior session close of $61.09. The primary catalyst is a fresh analyst note from Scotiabank highlighting Globalstar's direct-to-device satellite connectivity bypassing cellular towers — most notably in Mexico — reinforcing the company's next-generation infrastructure thesis.
Shares of ADMA are declining approximately 12% in Wednesday's session, extending a steep two-day selloff. The primary catalyst is a short-seller research report published by Culper Research on March 24, 2026, alleging that ADMA engaged in channel stuffing to artificially inflate revenue growth.
Honeywell International (HON) and TransDigm Group (TDG) are prominent players in the aerospace and industrials sector, benefiting from rising air travel demand, defense spending, and aftermarket services. This stock comparison evaluates their business models, recent performance, and market positioning to help traders and investors assess relative strengths in the current environment. With global aviation recovery and geopolitical tensions supporting sector tailwinds, professionals seeking exposure to aerospace growth versus diversified industrials stability will find these insights relevant for portfolio decisions and relative performance analysis.
PL shares are surging approximately +15% in Wednesday's session, trading near $35.89, pushing back toward the stock's 52-week high of $36.28 set on March 20, 2026. Primary catalyst: Continued momentum from a blockbuster Q4 fiscal 2026 earnings report delivered March 19, which sent revenue 41% higher year-over-year to $86.8 million, well above the $78 million Wall Street consensus.
ASTS shares surged approximately +11.00% in active intraday trading on March 25, 2026, moving from a prior close of $86.98 to approximately $96.55. The primary driver is a broad space sector rally fueled by renewed SpaceX IPO speculation, lifting satellite and space-related equities across the board.
FUBO shares are set to open about 12% lower in Wednesday’s premarket session after closing the prior day at roughly $12.02. The decline follows a strong multi-week rally powered by balance-sheet news, including the repurchase of $140.2 million of 2026 convertible notes and improving profitability trends.
One & One Green Technologies Inc. (YDDL) shares are indicated down about 13% in Wednesday’s premarket session after closing the prior regular session at $12.00. The stock had just surged 15.6% in the latest completed session, jumping from a prior close of $10.38 to $12.00, leaving it vulnerable to swift profit‑taking and volatility.
AVXL shares are indicated down about 33% in Wednesday’s premarket session, after closing the prior regular session at $4.19. The slide follows a recent drop triggered by a wider‑than‑expected fourth‑quarter loss and ongoing questions about the company’s late‑stage neurology pipeline.
AUGO shares are trading roughly 9% higher in Wednesday action, moving from a prior close of $66.42 to around $72.40 intraday. The stock’s advance extends a powerful year-long rally underpinned by record 2025 production, surging Adjusted EBITDA, and a recently declared cash dividend of $0.66 per share.
NAVN shares are surging approximately +25% in premarket trading on March 26, 2026, following a blockbuster earnings report released after the close of the prior session. Primary catalyst: Q4 fiscal year 2026 results delivered a significant beat — revenue of $178 million rose 35% year-over-year, surpassing analyst forecasts by nearly 10%.
OLPX surged approximately +50.38% in premarket trading on March 26, 2026, from a previous close of $1.33 to approximately $2.00, with an intraday premarket high of $2.03. The primary catalyst is a definitive acquisition agreement by German consumer goods giant Henkel AG to purchase Olaplex for $2.06 per share in an all-cash deal, valuing the company at approximately $1.4 billion.
TASK shares are down approximately -36% in premarket trading on March 26, 2026, the stock's official ex-dividend date for its special $3.65 per share cash dividend. The $3.65 special cash dividend — exceeding 25% of the stock's pre-ex-div market value — triggered a mandatory Nasdaq-prescribed price adjustment on today's open.
MLKN shares are down approximately 18.90% in premarket trading on March 26, 2026, falling to $15.70 from the prior session's close of $19.36. The primary catalyst is a double miss on both earnings and revenue in the company's fiscal Q3 2026 report released after the close on March 25.
Wave Life Sciences (WVE) shares are tumbling approximately 51% in premarket trading on March 26, 2026, from a prior close of $12.30 to approximately $6.03. The primary catalyst is the release of highly anticipated INLIGHT Phase 1 clinical data for WVE-007, the company's investigational INHBE GalNAc-siRNA obesity treatment, with results falling materially short of investor expectations.
APP is trading approximately 6% lower in premarket trading on March 26, 2026, extending a multi-session losing streak. The prior regular-session close (March 25, 2026) stood at $435.91, itself already down 5.02% from the day before, making the premarket slide a continuation of accelerating selling pressure.
KOD shares surged approximately +50% in premarket trading on Thursday, March 26, 2026, from a prior closing price of $22.75 to approximately $34.13. The primary catalyst is a landmark readout: the GLOW2 Phase 3 trial of Zenkuda (tarcocimab tedromer) in diabetic retinopathy met its primary endpoint with overwhelming statistical significance.